The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics
Background: Migraine has a negative impact on patients’ quality of life, with the frequency of attacks being associated with greater disability and poorer health status. Frequent migraine-type headaches require prophylactic treatment, which has so far been of limited effectiveness until advent of c...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Vilnius University Press
2024-05-01
|
| Series: | Acta Medica Lituanica |
| Subjects: | |
| Online Access: | https://www.journals.vu.lt/AML/article/view/33184 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593381938692096 |
|---|---|
| author | Monika Remenčiūtė Greta Varžaitytė Gintarė Žemgulytė |
| author_facet | Monika Remenčiūtė Greta Varžaitytė Gintarė Žemgulytė |
| author_sort | Monika Remenčiūtė |
| collection | DOAJ |
| description |
Background: Migraine has a negative impact on patients’ quality of life, with the frequency of attacks being associated with greater disability and poorer health status. Frequent migraine-type headaches require prophylactic treatment, which has so far been of limited effectiveness until advent of calcitonin gene-related peptide (CGRP) monoclonal antibody.Materials and Methods: A prospective analysis was conducted of data from 41 migraine patients who experienced 4 or more monthly migraine days (MMD) longer than three months. At the beginning of the study, treatment with monoclonal antibodies against CGRP (fremanezumab 225 mg or erenumab 70 or 140 g per month) was prescribed according to the indications. The effect of the medications was evaluated after 3-month period.Results: The mean age of patients was 37.17 (±11.78) years. It was found that 17 patients (41.5%) had episodic migraine (EM) and 24 (58.5%) had chronic migraine (CM). Fremanezumab was prescribed to 26 patients (63.4%) and erenumab to 15 patients (36.6%); among the latter, 13 patients used 70 mg/month and 2 patients used 140 mg/month. Three months after treatment, CM changed to EM for 19 patients (79.2%), 27 patients (65.9%) had ≥50% reduction in the number of MMD and total migraine disability assessment (MIDAS) score was reduced by >50% in 31 patients (75.6%). Also, all areas of quality of life of patients were improved after 3 months continued treatment compared to baseline.Conclusions: For more than half the patients using fremanezumab or erenumab after 3-month period, MMD decreased by ≥50% and total MIDAS score by >50 points. All areas of quality of life were improved after prophylactic treatment of migraine.
|
| format | Article |
| id | doaj-art-41ad6a4ca7c948289f1414016217d243 |
| institution | Kabale University |
| issn | 1392-0138 2029-4174 |
| language | English |
| publishDate | 2024-05-01 |
| publisher | Vilnius University Press |
| record_format | Article |
| series | Acta Medica Lituanica |
| spelling | doaj-art-41ad6a4ca7c948289f1414016217d2432025-01-20T18:07:59ZengVilnius University PressActa Medica Lituanica1392-01382029-41742024-05-0131110.15388/Amed.2024.31.1.12The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas ClinicsMonika Remenčiūtė0Greta Varžaitytė1Gintarė Žemgulytė2https://orcid.org/0000-0003-4496-9668Kaunas Hospital of the Lithuanian University of Health Sciences, Kaunas, LithuaniaLithuanian University of Health Sciences, Medical Academy, Faculty of Medicine, Department of Neurology, Kaunas, LithuaniaLithuanian University of Health Sciences, Medical Academy, Faculty of Medicine, Department of Neurology, Kaunas, Lithuania Background: Migraine has a negative impact on patients’ quality of life, with the frequency of attacks being associated with greater disability and poorer health status. Frequent migraine-type headaches require prophylactic treatment, which has so far been of limited effectiveness until advent of calcitonin gene-related peptide (CGRP) monoclonal antibody.Materials and Methods: A prospective analysis was conducted of data from 41 migraine patients who experienced 4 or more monthly migraine days (MMD) longer than three months. At the beginning of the study, treatment with monoclonal antibodies against CGRP (fremanezumab 225 mg or erenumab 70 or 140 g per month) was prescribed according to the indications. The effect of the medications was evaluated after 3-month period.Results: The mean age of patients was 37.17 (±11.78) years. It was found that 17 patients (41.5%) had episodic migraine (EM) and 24 (58.5%) had chronic migraine (CM). Fremanezumab was prescribed to 26 patients (63.4%) and erenumab to 15 patients (36.6%); among the latter, 13 patients used 70 mg/month and 2 patients used 140 mg/month. Three months after treatment, CM changed to EM for 19 patients (79.2%), 27 patients (65.9%) had ≥50% reduction in the number of MMD and total migraine disability assessment (MIDAS) score was reduced by >50% in 31 patients (75.6%). Also, all areas of quality of life of patients were improved after 3 months continued treatment compared to baseline.Conclusions: For more than half the patients using fremanezumab or erenumab after 3-month period, MMD decreased by ≥50% and total MIDAS score by >50 points. All areas of quality of life were improved after prophylactic treatment of migraine. https://www.journals.vu.lt/AML/article/view/33184chronic migrainecalcitonin gene-related peptide monoclonal antibodiesMigraine Disability Assessment36-Item Short Form Survey Instrument questionnaire |
| spellingShingle | Monika Remenčiūtė Greta Varžaitytė Gintarė Žemgulytė The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics Acta Medica Lituanica chronic migraine calcitonin gene-related peptide monoclonal antibodies Migraine Disability Assessment 36-Item Short Form Survey Instrument questionnaire |
| title | The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics |
| title_full | The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics |
| title_fullStr | The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics |
| title_full_unstemmed | The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics |
| title_short | The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics |
| title_sort | effect of calcitonin gene related peptide monoclonal antibodies on quality of life among migraine patients pilot study at the hospital of lithuanian university of health sciences kaunas clinics |
| topic | chronic migraine calcitonin gene-related peptide monoclonal antibodies Migraine Disability Assessment 36-Item Short Form Survey Instrument questionnaire |
| url | https://www.journals.vu.lt/AML/article/view/33184 |
| work_keys_str_mv | AT monikaremenciute theeffectofcalcitoningenerelatedpeptidemonoclonalantibodiesonqualityoflifeamongmigrainepatientspilotstudyatthehospitaloflithuanianuniversityofhealthscienceskaunasclinics AT gretavarzaityte theeffectofcalcitoningenerelatedpeptidemonoclonalantibodiesonqualityoflifeamongmigrainepatientspilotstudyatthehospitaloflithuanianuniversityofhealthscienceskaunasclinics AT gintarezemgulyte theeffectofcalcitoningenerelatedpeptidemonoclonalantibodiesonqualityoflifeamongmigrainepatientspilotstudyatthehospitaloflithuanianuniversityofhealthscienceskaunasclinics AT monikaremenciute effectofcalcitoningenerelatedpeptidemonoclonalantibodiesonqualityoflifeamongmigrainepatientspilotstudyatthehospitaloflithuanianuniversityofhealthscienceskaunasclinics AT gretavarzaityte effectofcalcitoningenerelatedpeptidemonoclonalantibodiesonqualityoflifeamongmigrainepatientspilotstudyatthehospitaloflithuanianuniversityofhealthscienceskaunasclinics AT gintarezemgulyte effectofcalcitoningenerelatedpeptidemonoclonalantibodiesonqualityoflifeamongmigrainepatientspilotstudyatthehospitaloflithuanianuniversityofhealthscienceskaunasclinics |